孙建博

师资队伍

当前位置：蘑菇视频师资队伍天然药物化学系教授/（特聘）研究员

孙建博

教授博士生导师

电话：邮箱：[email protected]

办公室地址：

研究领域：1. 抑郁调控机制研究及快速抗抑郁药物的设计；2. 多特异性分子调节机制的新药发现与技术平台研究； 3. 天然活性物质研究与食品和化妆品的开发

招生方向：生物与医药--中药与食品工程,天然药物化学,中药学-中药化学与化学生物学,中药-中药活性物质研究与产品开发

[1] Zhou Xin-Yue^#, Xu Zhongyuan^#, Liu Xiwen^#, Wu Guiying, Hou Yudong, Qi Lian-Wen^*, Liu Qun^*, Sun Jianbo^*. Bifunctional LYTAC Mediates Hepatocytes-Hepatic Stellate Cells Crosstalk by Regulating 5HT2A Receptor Degradation and Antagonism to Synergistically Ameliorate Hepatic Fibrosis.J Am Chem Soc (IF: 15.7), 2025, 147(48): 44162-44174.
[2] Wang Menghua^#, Takudzwa Chiwoneso^#, Luo Zimeng^#, Justice Josiah Mallen, Xia Yuanzheng^*, Sun Jianbo^*. Cancer Pathogenesis and Phase Targeting through Condensate Fragility. Trends in Pharmacological Sciences(IF: 19.9), 2026, s0165-6147(26)00015-5.
[3] Peisen Zhong^#, Xinyu Mao^#, Na Li^#, Li Chen^*, andJianbo Sun^*. Development of Nitric Oxide Releasing Oxoisoaporphines with Antidepressant Activities by Simultaneously Regulating MAOA and SERT.J Med Chem, 2024, 67, 15509-15520.
[4] Qi Mingming^#, Zhong Hui^#, Cheng Zhaoyan^#, Chen Shujie, Xiao Han, Shang Jing, Chen Li^*, Sun Jianbo^*.Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1. J Med Chem, 2023, 66, 13, 9184-9200.
[5] Wang Kun^#, Zhong Hui^#, Li Na,Yu Nairong, Wang Yujin, Chen Li^*, Sun Jianbo^*. Discovery of Novel Anti-Breast-Cancer Inhibitors by SynergisticallyAntagonizing Microtubule Polymerization and Aryl Hydrocarbon ReceptorExpression, J Med Chem, 2021, 64, 12964-12977.
[6] Sun Xiaona^#, Li Na^#, Zhong Peisen, Chen Li^*, Sun Jianbo^*. Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity, J Med Chem, 2022, 65(19): 13385-13400.
[7] Li Na^#, Xu Manyi^#, Zhang Lulu, Lei Zhichao, Chen Cheng, Zhang Tianyuan, Chen Li^*,Sun Jianbo^*. Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo, J Med Chem, 2022, (65): 4578-4589.
[8] Sun Jianbo^#, Zhong Hui^#, Wang Kun, Li Na^*, Chen Li^*.Gains from no Real PAINS: Where ‘Fair Trial Strategy’ Stands in the Developmentof Multi-target Ligands. Acta Pharm Sin B. 2021, 11(11): 3417-3432.
- 第一页 <<上一页下一页>> 尾页
- 页码 4/4
天然药物化学，波谱解析
[1] Zhou Xin-Yue^#, Xu Zhongyuan^#, Liu Xiwen^#, Wu Guiying, Hou Yudong, Qi Lian-Wen^*, Liu Qun^*, Sun Jianbo^*. Bifunctional LYTAC Mediates Hepatocytes-Hepatic Stellate Cells Crosstalk by Regulating 5HT2A Receptor Degradation and Antagonism to Synergistically Ameliorate Hepatic Fibrosis.J Am Chem Soc (IF: 15.7), 2025, 147(48): 44162-44174.
[2] Wang Menghua^#, Takudzwa Chiwoneso^#, Luo Zimeng^#, Justice Josiah Mallen, Xia Yuanzheng^*, Sun Jianbo^*. Cancer Pathogenesis and Phase Targeting through Condensate Fragility. Trends in Pharmacological Sciences(IF: 19.9), 2026, s0165-6147(26)00015-5.
[3] Peisen Zhong^#, Xinyu Mao^#, Na Li^#, Li Chen^*, andJianbo Sun^*. Development of Nitric Oxide Releasing Oxoisoaporphines with Antidepressant Activities by Simultaneously Regulating MAOA and SERT.J Med Chem, 2024, 67, 15509-15520.
[4] Qi Mingming^#, Zhong Hui^#, Cheng Zhaoyan^#, Chen Shujie, Xiao Han, Shang Jing, Chen Li^*, Sun Jianbo^*.Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1. J Med Chem, 2023, 66, 13, 9184-9200.
[5] Wang Kun^#, Zhong Hui^#, Li Na,Yu Nairong, Wang Yujin, Chen Li^*, Sun Jianbo^*. Discovery of Novel Anti-Breast-Cancer Inhibitors by SynergisticallyAntagonizing Microtubule Polymerization and Aryl Hydrocarbon ReceptorExpression, J Med Chem, 2021, 64, 12964-12977.
[6] Sun Xiaona^#, Li Na^#, Zhong Peisen, Chen Li^*, Sun Jianbo^*. Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity, J Med Chem, 2022, 65(19): 13385-13400.
[7] Li Na^#, Xu Manyi^#, Zhang Lulu, Lei Zhichao, Chen Cheng, Zhang Tianyuan, Chen Li^*,Sun Jianbo^*. Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo, J Med Chem, 2022, (65): 4578-4589.
[8] Sun Jianbo^#, Zhong Hui^#, Wang Kun, Li Na^*, Chen Li^*.Gains from no Real PAINS: Where ‘Fair Trial Strategy’ Stands in the Developmentof Multi-target Ligands. Acta Pharm Sin B. 2021, 11(11): 3417-3432.